EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Racial disparity in the genomics of precision oncology of prostate cancer

Tu Le iD, Pilar Soto Rojas iD, Mary Fakunle, Franklin W Huang

Cancer Reports · 2023

DOI: 10.1002/cnr2.1867 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Reports, 2023. Verfasst von Tu Le und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Genome-Wide Association Study, Prostatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Significant racial disparities in prostate cancer incidence and mortality have been reported between African American Men (AAM), who are at increased risk for prostate cancer, and European American Men (EAM). In most of the studies carried out on prostate cancer, this population is underrepresented. With the advancement of genome‐wide association studies, several genetic predictor models of prostate cancer risk have been elaborated, as well as numerous studies that identify both germline and somatic mutations with clinical utility. Recent Findings Despite significant advances, the AAM population continues to be underrepresented in genomic studies, which can limit generalizability and potentially widen disparities. Here we outline racial disparities in currently available genomic applications that are used to estimate the risk of individuals developing prostate cancer and to identify personalized oncology treatment strategies. While the incidence and mortality of prostate cancer are different between AAM and EAM, samples from AAM remain to be unrepresented in different studies.

Conclusion

This disparity impacts the available genomic data on prostate cancer. As a result, the disparity can limit the predictive utility of the genomic applications and may lead to the widening of the existing disparities. More studies with substantially higher recruitment and engagement of African American patients are necessary to overcome this disparity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genome-Wide Association StudyProstatic NeoplasmsMaleHumansPrecision MedicineGenomicsWhite

Stichwörter der Autor:innen

Decipher testclinical trial enrollmentgermline and somatic testpolygenic risk scoresprostate cancerracial disparity

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA.
  • Division of Hematology and Oncology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
  • Department of Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Department of Urology, University of California, San Francisco, California, USA.
  • Chan Zuckerberg Biohub, San Francisco, California, USA.
  • Institute for Human Genetics, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Tu Le, Pilar Soto Rojas

Zitieren

APA

Le, T., Rojas, P. S., Fakunle, M., & Huang, F. W. (2023). Racial disparity in the genomics of precision oncology of prostate cancer. Cancer Reports. https://doi.org/10.1002/cnr2.1867

Vancouver

Le T, Rojas PS, Fakunle M, Huang FW. Racial disparity in the genomics of precision oncology of prostate cancer. Cancer Reports. 2023. doi:10.1002/cnr2.1867

BibTeX
@article{Le2023,
  author = {Le, Tu and Rojas, Pilar Soto and Fakunle, Mary and Huang, Franklin W},
  title = {Racial disparity in the genomics of precision oncology of prostate cancer},
  journal = {Cancer Reports},
  year = {2023},
  doi = {10.1002/cnr2.1867}
}
Kostenlos starten →